« Return to News | Clinical Intelligence

The CenterWatch Monthly, August 2013

Friday, August 2, 2013 10:36 AM

Will end-to-end outsourcing take hold?

Decisions for and against vertical integration are creating wider differences among CROs. Industry analysts and observers are closely watching the success of global CROs—including Covance and WuXi PharmaTech—that offer a broad range of services across the R&D spectrum, to see if other leading CROs will move toward expanding portfolios beyond their established clinical research services domain.

 

Medical device outsourcing poised to grow rapidly

More sponsors using larger, complex clinical trials to enhance product positioning. Medical device companies increasingly turn to CROs for clinical development work as they look for cost-effective and efficient ways to meet rising regulatory demands and pressures to expand into global markets...

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information. - See more at: http://www.centerwatch.com/news-online/article/4947/Preview#sthash.gIBrlPWE.dpuf
Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.